Survival outcomes in patients with advanced non-small cell lung cancer treated with erlotinib: expanded access programme data from Belgium (the TRUST study)-Reference-Cited by-同舟云学术

Survival outcomes in patients with advanced non-small cell lung cancer treated with erlotinib: expanded access programme data from Belgium (the TRUST study)

Published:2013-10-24 Issue:3 Volume:23 Page:370-379
ISSN:0961-5423
Container-title:European Journal of Cancer Care
language:en
Short-container-title:Eur J Cancer Care (Engl)

Author:

Van Meerbeeck J.¹,Galdermans D.²,Bustin F.³,De Vos L.⁴,Lechat I.⁴,Abraham I.⁵

Affiliation:

1. Thoracic Oncology; Ghent University Hospital; Gent Belgium

2. Department of Respiratory Medicine; ZNA Middelheim; Antwerpen Belgium

3. Department of Respiratory Medicine; Centre Hospitalier Régional de la Citadelle; Liège Belgium

4. Roche; Brussel Belgium

5. Center for Health Outcomes and Pharmacoeconomic Research; College of Pharmacy; University of Arizona; Tucson AZ USA

Publisher

Wiley

Subject

Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ecc.12146/fullpdf

Reference15 articles.

1. Belgian Cancer Registry 2013 http://www.kankerregister.org

2. Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy. 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010;Felip;Annals of Oncology,2011

3. Epidemiology of tobacco use in the United States;Giovino;Oncogene,2002

4. Developing inhibitors of the epidermal growth factor receptor for cancer treatment;Grunwald;Journal of the National Cancer Institute,2003

5. Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study;Heigener;Lung Cancer,2011

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First-Third generation EGFR inhibitor combined with cytotoxic chemotherapy in elderly Patients with advanced lung adenocarcinom in routine clinical practice-results from A Subgroup Analysis;2022-09-01

2. Performance Status and Age as Predictors of Immunotherapy Outcomes in Advanced Non–Small-Cell Lung Cancer;Clinical Lung Cancer;2020-07

3. Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice – results from the ElderTac study;BMC Cancer;2018-03-27

4. Corneal edema with a systemic epidermal growth factor receptor inhibitor;Canadian Journal of Ophthalmology;2017-06

5. The strange connection between epidermal growth factor receptor tyrosine kinase inhibitors and dapsone: from rash mitigation to the increase in anti-tumor activity;Current Medical Research and Opinion;2016-08-11